A production line of anti-diabetes injection is pictured at a workshop of Novo Nordisk (China) Pharmaceutical Co., Ltd. in Tianjin, north China, Sept. 22, 2022. Over the past 20 years, Novo Nordisk, a pharmaceutical company from Denmark, has continuously increased its investment in China. Now, Novo Nordisk has already established a full value chain in the country, with one of its biggest manufacturing bases in Tianjin that supplies both Chinese and international markets with durable devices for insulin injection and insulin products. (Xinhua/Li Ran)

A staff member works at a lab of Novo Nordisk (China) Pharmaceutical Co., Ltd. in Tianjin, north China, Sept. 22, 2022. Over the past 20 years, Novo Nordisk, a pharmaceutical company from Denmark, has continuously increased its investment in China. Now, Novo Nordisk has already established a full value chain in the country, with one of its biggest manufacturing bases in Tianjin that supplies both Chinese and international markets with durable devices for insulin injection and insulin products. (Xinhua/Li Ran)

A staff member works at a workshop of Novo Nordisk (China) Pharmaceutical Co., Ltd. in Tianjin, north China, Sept. 22, 2022. Over the past 20 years, Novo Nordisk, a pharmaceutical company from Denmark, has continuously increased its investment in China. Now, Novo Nordisk has already established a full value chain in the country, with one of its biggest manufacturing bases in Tianjin that supplies both Chinese and international markets with durable devices for insulin injection and insulin products. (Xinhua/Li Ran)

Staff members work at a workshop of Novo Nordisk (China) Pharmaceutical Co., Ltd. in Tianjin, north China, Sept. 22, 2022. Over the past 20 years, Novo Nordisk, a pharmaceutical company from Denmark, has continuously increased its investment in China. Now, Novo Nordisk has already established a full value chain in the country, with one of its biggest manufacturing bases in Tianjin that supplies both Chinese and international markets with durable devices for insulin injection and insulin products. (Xinhua/Li Ran)

Staff members work at a workshop of Novo Nordisk (China) Pharmaceutical Co., Ltd. in Tianjin, north China, Sept. 22, 2022. Over the past 20 years, Novo Nordisk, a pharmaceutical company from Denmark, has continuously increased its investment in China. Now, Novo Nordisk has already established a full value chain in the country, with one of its biggest manufacturing bases in Tianjin that supplies both Chinese and international markets with durable devices for insulin injection and insulin products. (Xinhua/Li Ran)

A film wrapping robot carries out packaging operation at a workshop of Novo Nordisk (China) Pharmaceutical Co., Ltd. in Tianjin, north China, Sept. 22, 2022. Over the past 20 years, Novo Nordisk, a pharmaceutical company from Denmark, has continuously increased its investment in China. Now, Novo Nordisk has already established a full value chain in the country, with one of its biggest manufacturing bases in Tianjin that supplies both Chinese and international markets with durable devices for insulin injection and insulin products. (Xinhua/Li Ran)

A staff member works at a lab of Novo Nordisk (China) Pharmaceutical Co., Ltd. in Tianjin, north China, Sept. 22, 2022. Over the past 20 years, Novo Nordisk, a pharmaceutical company from Denmark, has continuously increased its investment in China. Now, Novo Nordisk has already established a full value chain in the country, with one of its biggest manufacturing bases in Tianjin that supplies both Chinese and international markets with durable devices for insulin injection and insulin products. (Xinhua/Li Ran)